Rhythm is a public biopharmaceutical company dedicated to changing how rare genetic disorders of obesity are diagnosed and treated located in Boston’s Back Bay neighborhood. Rhythm’s MC4R agonist, setmelanotide, is being evaluated in multiple late-stage clinical studies to treat disorders of severe obesity. These disorders may result from genetic variants within the melanocortin-4 receptor (MC4R) pathway, a key pathway responsible for regulating weight, that lead to excessive or insatiable hunger or hyperphagia. The company is also leading efforts to improve patient identification and diagnosis through genetic testing and deepen the community’s understanding of the ongoing impact and burden of disease on patients and caregivers. Learn more at www.rhythmtx.com.